OneSource Specialty Pharma (ONESOURCE) Q4 23/24 earnings summary

Executive summary

• FY24 marked a turnaround in quarterly operations: Q4 delivered the highest quarterly revenue and the first EBITDA-positive quarter; annual losses remained substantial.

• The sale of Unit 3 to Syngene reduced debt by more than 50%; the planned integration of soft gelatin and complex-injectable businesses is intended to broaden offerings and create operating synergies.

• FY25 priorities include converting signed manufacturing agreements into commercial supply, launching Teriparatide, expanding capacity and completing the business integration.

Financial highlights

• Standalone revenue from operations was ₹1,719.19 million in FY24 vs ₹387.14 million in FY23; total income was ₹1,761.44 million vs ₹414.18 million.

• Standalone loss before exceptional items and tax was ₹2,490.00 million vs ₹2,711.41 million; exceptional loss was ₹1,159.34 million vs ₹1,584.13 million.

• Standalone loss for the year was ₹3,904.02 million vs ₹7,991.12 million; consolidated loss was ₹3,911.65 million vs ₹7,998.30 million.

• Consolidated FY24 revenue was ₹1,719.19 million; Q4 delivered record quarterly revenue and positive EBITDA for the first time.

Outlook and guidance

• FY25 revenue growth is expected to be significant, supported by the order book, signed agreements and project pipeline; the stated goal is a fully positive year.

• Projected commercial sales agreement revenue from signed customers is $382 million for FY25–FY28.

• Teriparatide commercialization was targeted for Q1 FY25 following EMA approval and customer contracts; a new high-speed vial line was planned for FY25.

• Completion of the consolidation scheme was expected by December 2024; the integration was also described as targeted by fiscal year-end.